Report cover image

Global Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Feb 11, 2025
Length 199 Pages
SKU # APRC19856745

Description

Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.


Peptide Cancer Vaccine Segment by Company

Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science

Peptide Cancer Vaccine Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others

Peptide Cancer Vaccine Segment by Application

Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others

Peptide Cancer Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Peptide Cancer Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global Peptide Cancer Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Peptide Cancer Vaccine Market Dynamics
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 Peptide Cancer Vaccine Market by Manufacturers
3.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global Peptide Cancer Vaccine Sales by Manufacturers (2020-2025)
3.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
3.7 Global Peptide Cancer Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
4 Peptide Cancer Vaccine Market by Type
4.1 Peptide Cancer Vaccine Type Introduction
4.1.1 ITK-1
4.1.2 GRN-1201
4.1.3 TPIV200
4.1.4 TPIV110
4.1.5 UV1
4.1.6 Galinpepimut-S
4.1.7 TARP 27-35
4.1.8 HER-Vaxx
4.1.9 Vx-001
4.1.10 Others
4.2 Global Peptide Cancer Vaccine Sales by Type
4.2.1 Global Peptide Cancer Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Peptide Cancer Vaccine Sales by Type (2020-2031)
4.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2020-2031)
4.3 Global Peptide Cancer Vaccine Revenue by Type
4.3.1 Global Peptide Cancer Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Peptide Cancer Vaccine Revenue by Type (2020-2031)
4.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2020-2031)
5 Peptide Cancer Vaccine Market by Application
5.1 Peptide Cancer Vaccine Application Introduction
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Sales by Application
5.2.1 Global Peptide Cancer Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Peptide Cancer Vaccine Sales by Application (2020-2031)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2020-2031)
5.3 Global Peptide Cancer Vaccine Revenue by Application
5.3.1 Global Peptide Cancer Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Peptide Cancer Vaccine Revenue by Application (2020-2031)
5.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2031)
6 Global Peptide Cancer Vaccine Sales by Region
6.1 Global Peptide Cancer Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Peptide Cancer Vaccine Sales by Region (2020-2031)
6.2.1 Global Peptide Cancer Vaccine Sales by Region (2020-2025)
6.2.2 Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Peptide Cancer Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Peptide Cancer Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Peptide Cancer Vaccine Revenue by Region
7.1 Global Peptide Cancer Vaccine Revenue by Region
7.1.1 Global Peptide Cancer Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Peptide Cancer Vaccine Revenue by Region (2020-2025)
7.1.3 Global Peptide Cancer Vaccine Revenue by Region (2026-2031)
7.1.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Peptide Cancer Vaccine Revenue (2020-2031)
7.2.2 North America Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Peptide Cancer Vaccine Revenue (2020-2031)
7.3.2 Europe Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Peptide Cancer Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Peptide Cancer Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Boston Biomedical
8.1.1 Boston Biomedical Comapny Information
8.1.2 Boston Biomedical Business Overview
8.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
8.1.5 Boston Biomedical Recent Developments
8.2 Ultimovacs
8.2.1 Ultimovacs Comapny Information
8.2.2 Ultimovacs Business Overview
8.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
8.2.5 Ultimovacs Recent Developments
8.3 BrightPath Biotherapeutics
8.3.1 BrightPath Biotherapeutics Comapny Information
8.3.2 BrightPath Biotherapeutics Business Overview
8.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
8.3.5 BrightPath Biotherapeutics Recent Developments
8.4 TapImmune
8.4.1 TapImmune Comapny Information
8.4.2 TapImmune Business Overview
8.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
8.4.5 TapImmune Recent Developments
8.5 Immatics
8.5.1 Immatics Comapny Information
8.5.2 Immatics Business Overview
8.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
8.5.5 Immatics Recent Developments
8.6 Sellas
8.6.1 Sellas Comapny Information
8.6.2 Sellas Business Overview
8.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
8.6.5 Sellas Recent Developments
8.7 Imugene
8.7.1 Imugene Comapny Information
8.7.2 Imugene Business Overview
8.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
8.7.5 Imugene Recent Developments
8.8 VAXON Biotech
8.8.1 VAXON Biotech Comapny Information
8.8.2 VAXON Biotech Business Overview
8.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
8.8.5 VAXON Biotech Recent Developments
8.9 Generex Biotechnology
8.9.1 Generex Biotechnology Comapny Information
8.9.2 Generex Biotechnology Business Overview
8.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
8.9.5 Generex Biotechnology Recent Developments
8.10 ISA Pharmaceuticals
8.10.1 ISA Pharmaceuticals Comapny Information
8.10.2 ISA Pharmaceuticals Business Overview
8.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
8.10.5 ISA Pharmaceuticals Recent Developments
8.11 OncoTherapy Science
8.11.1 OncoTherapy Science Comapny Information
8.11.2 OncoTherapy Science Business Overview
8.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
8.11.5 OncoTherapy Science Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Peptide Cancer Vaccine Value Chain Analysis
9.1.1 Peptide Cancer Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Peptide Cancer Vaccine Production Mode & Process
9.2 Peptide Cancer Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Peptide Cancer Vaccine Distributors
9.2.3 Peptide Cancer Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.